SEC Form 4 · accession 0001144204-17-013011
Inspyr Therapeutics, Inc. · NSPX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Varde Ogilvie
Director
Period of report
Mar 3, 2017
Accepted (ET)
Mar 6, 2017 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001421204
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock purchase optionF1 | $0.54 | Mar 3, 2017 | A | 2,335 | A | Mar 3, 2017 | Mar 3, 2022 | Common Stock | 2,335 | 2,335 | D |
Explanation of responses
- F1Represents compensatory Annual Grant and Committee Grants for director services. The options vest quarterly on 6/3/17, 9/3/17, 12/3/17, and 3/3/18.